The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4- ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma

European Journal of Cancer

Volumn 47, Issue 8, 2011, Pages 1219-1230

  Tentori, Lucio ^a   Dorio, Annalisa Susanna ^a   Mazzon, Emanuela ^b   Muzi, Alessia ^a   Sau, Andrea ^a   Cuzzocrea, Salvatore ^b,c   Vernole, Patrizia ^a   Federici, Giorgio ^d   Caccuri, Anna Maria ^a   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Chemotherapy; Drug resistance; Glutathione transferase inhibitors; Melanoma; Methylating agents

Indexed keywords

6 (7 NITRO 2,1,3 BENZOXADIAZOL 4 YLTHIO)HEXANOL; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; CYCLIN D1; GLUTATHIONE TRANSFERASE P1; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TEMOZOLOMIDE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE COUNT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DNA METHYLATION; DRUG SYNERGISM; GLUTATHIONE TRANSFERASE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; OXADIAZOLES;

EID: 79955539543     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.12.008     Document Type: Article

References (35)

1. E.L. Korn, P.Y. Liu, and S.J. Lee Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials J Clin Oncol 26 2008 527 534 (Pubitemid 351264344)
2. M.R. Middleton, J.J. Grob, and N. Aaronson Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 2000 158 166 (Pubitemid 30036349)
3. G.M. Kiebert, D.L. Jonas, and M.R. Middleton Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine Cancer Invest 21 2003 821 829 (Pubitemid 38055978)
4. V.A. Trinh, S.P. Patel, and W.J. Hwu The safety of temozolomide in the treatment of malignancies Expert Opin Drug Saf 8 2009 493 499
5. E. Wierzbicka-Hainaut, B. Sassolas, and L. Mourey Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial Melanoma Res 20 2010 141 146
6. M.B. Atkins, J.A. Sosman, and S. Agarwala Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II cytokine working group study Cancer 113 2008 2139 2145
7. J. Glaspy, M.B. Atkins, and J.M. Richards Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma Cancer 115 2009 5228 5236
8. B. Guillot, A. Khamari, and D. Cupissol Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study Melanoma Res 18 2008 141 146 (Pubitemid 351398269)
9. R.K. Amaravadi, L.M. Schuchter, and D.F. McDermott Phase II Trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases Clin Cancer Res 15 2009 7711 7718
10. E.S. Newlands, M.F. Stevens, S.R. Wedge, R.T. Wheelhouse, and C. Brock Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 1997 35 61 (Pubitemid 27273454)
11. L. Tentori, and G. Graziani Recent approaches to improve the antitumour efficacy of temozolomide Curr Med Chem 16 2009 245 257
12. L. Tentori, C. Leonetti, and M. Scarsella Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumours Int J Oncol 26 2005 415 422
13. P. Turella, G. Filomeni, and M.L. Dupuis A strong glutathione S-transferase inhibitor overcomes the p-glycoprotein-mediated resistance in tumour cells. 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells J Biol Chem 281 2006 23725 23732 (Pubitemid 44274147)
14. F. Pellizzari Tregno, A. Sau, and S. Pezzola In vitro and in vivo efficacy of 6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma Eur J Cancer 45 2009 2606 2617
15. G. Filomeni, P. Turella, and M.L. Dupuis 6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer Mol Cancer Ther 7 2008 371 379 (Pubitemid 351302530)
16. M. Pasello, F. Michelacci, and I. Scionti Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma Cancer Res 68 2008 6661 6668
17. A. Ascione, M. Cianfriglia, and M.L. Dupuis The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells Cancer Chemother Pharmacol 64 2009 419 424
18. L. Tentori, A. Muzi, and A.S. Dorio Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity Eur J Cancer 44 2008 1302 1314
19. G. Ricci, F. De Maria, and G. Antonini 7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs J Biol Chem 280 2005 26397 26405 (Pubitemid 41022236)
20. L. Tentori, C. Leonetti, and M. Scarsella Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumour activity of temozolomide against intracranial melanoma, glioma, lymphoma Clin Cancer Res 9 2003 5370 5379 (Pubitemid 37413592)
21. L. Tentori, A. Muzi, and A.S. Dorio Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent Curr Cancer Drug Targets 10 2010 368 383
22. P. Turella, C. Cerella, and G. Filomeni Proapoptotic activity of new glutathione S-transferase inhibitors Cancer Res 65 2005 3751 3761 (Pubitemid 40616353)
23. P. Lopez-Bergami, C. Huang, and J.S. Goydos Rewired ERK-JNK signaling pathways in melanoma Cancer Cell 11 2007 447 460 (Pubitemid 46670078)
24. A. Sau, F.P. Tregno, F. Valentino, G. Federici, and A.M. Caccuri Glutathione transferases and development of new principles to overcome drug resistance Arch Biochem Biophys 500 2010 116 122
25. N.M. Mhaidat, X.D. Zhang, and J. Allen Temozolomide induces senescence but not apoptosis in human melanoma cells Br J Cancer 97 2007 1225 1233 (Pubitemid 350035808)
26. M. Chen, A.E. Rose, N. Doudican, I. Osman, and S.J. Orlow Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells Mol Cancer Res 7 2009 1946 1953
27. S. Ohba, Y. Hirose, T. Kawase, and H. Sano Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells J Neurooncol 95 2009 307 316
28. S.Y. Fuchs, V. Adler, M.R. Pincus, and Z. Ronai MEKK1/JNK signaling stabilizes and activates p53 Proc Natl Acad Sci USA 95 1998 10541 10546 (Pubitemid 28413103)
29. S. Li, T. Jiang, G. Li, and Z. Wang Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results Neurol Res 30 2008 567 570 (Pubitemid 352032552)
30. Y. Yoshimoto, C.K. Augustine, and J.S. Yoo Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents Mol Cancer Ther 6 2007 1492 1500 (Pubitemid 46954016)
31. P.M. Lacal, F. Ruffini, E. Pagani, and S. D'Atri An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells Int J Oncol 27 2005 1625 1632
32. M. Ranson, P. Hersey, and D. Thompson Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma J Clin Oncol 25 2007 2540 2545 (Pubitemid 47041227)
33. A.A. Tarhini, J.M. Kirkwood, W.E. Gooding, S. Moschos, and S.S. Agarwala A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma Cancer 113 2008 1632 1640
34. J.E. Ruscoe, L.A. Rosario, and T. Wang Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways J Pharmacol Exp Ther 298 2001 339 345 (Pubitemid 32574545)
35. A. Raza, N. Galili, and N. Callander Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome J Hematol Oncol 2 2009 20